Abstract: We report a patient with refractory bullous pemphigoid was treated with glucocorticoid at first, but the effect was poor. Rituximab was used for treatment, and the rash recurred with severe pruritus. After oral administration of the JAK1 inhibitor abrocitinib, the pruritus was rapidly relieved, and there was no recurrence of the rash during follow-up.

Key words: bullous pemphigoid, pruritus, JAK inhibitors, adverse effects